US equities
|
NVDA
$239.72
▲+0.34%
MU
$1,053.70
▼-0.96%
SPCX
$172.60
▲+0.89%
MRVL
$290.32
▲+7.03%
AMD
$654.39
▲+3.58%
INTC
$114.08
▼-1.82%
AVGO
$377.32
▲+4.09%
TSLA
$380.08
▲+0.36%
NVDA
$239.72
▲+0.34%
MU
$1,053.70
▼-0.96%
SPCX
$172.60
▲+0.89%
MRVL
$290.32
▲+7.03%
AMD
$654.39
▲+3.58%
INTC
$114.08
▼-1.82%
AVGO
$377.32
▲+4.09%
TSLA
$380.08
▲+0.36%
FinancialContent
Sign in
Markets
Overview
News
World markets
Treasuries
Currencies
Commodities
Economy
Stocks
Overview
Most active
Gainers
Losers
Largest companies
52-week gainers
52-week losers
ETFs
Overview
Popular funds
Most active
Gainers
Losers
News
Research
Search
Sectors
Akebia Therapeutics, Inc. - Common Stock
(NQ:
AKBA
)
0.8783
-0.0322 (-3.54%)
Delayed Quote
Updated: 3:21 PM EDT, Oct 6, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Akebia Therapeutics, Inc. - Common Stock
Akebia Therapeutics Surges on FDA Approval for Anemia Treatment
April 03, 2024
Akebia Therapeutics Inc. (NASDAQ: AKBA) is a biopharmaceutical company specializing in developing treatments for chronic kidney diseases (CKD) and anemia
Via
MarketBeat
Akebia Therapeutics Inc. (NASDAQ: AKBA) is One of Thursday Morning’s Most Active Stocks
March 28, 2024
Via
Investor Brand Network
Mighty Mitochondria: This Company is Developing A Novel Drug for Kidney Disease By Targeting The Powerhouse Of Human Cells
October 12, 2022
You may remember learning that mitochondria are the powerhouse of the cells, but do you know the dangers that result if these cell superheroes get sick?
Via
TheNewswire.com
How One Company Plans To Help Battle A Silent Killer Globally Through Its New Kidney Disease Medication
September 23, 2022
Most people are surprised to learn that chronic kidney disease (CKD) is the fastest growing, non-communicable disease in the United States. 37 million American adults have CKD and more than 600,000...
Via
TheNewswire.com
Akebia Therapeutics, Inc. (NASDAQ:AKBA) Long Term Investor Alert: Investigation of Potential Wrongdoing
↗
June 20, 2022
San Diego, CA -- (SBWIRE) -- 06/20/2022 -- An investigation was announced concerning potential breaches of fiduciary duties by certain directors and officers of Akebia Therapeutics, Inc..
Via
SBWire
AKEBIA DEADLINE ALERT: Bragar Eagel & Squire, P.C. Reminds Investors that a Class Action Lawsuit Has Been Filed Against Akebia Therapeutics, Inc. and Encourages Investors to Contact the Firm
May 11, 2022
From
Bragar Eagel & Squire, P.C.
Via
Business Wire
NASDAQ:AKBA Investor Notice: Deadline on May 13, 2022 in Lawsuit Against Akebia Therapeutics, Inc.
↗
May 10, 2022
San Diego, CA -- (SBWIRE) -- 05/10/2022 -- The Shareholders Foundation announced that a deadline is coming up on May 13, 2022 in the lawsuit filed for certain investors of Akebia Therapeutics, Inc....
Via
SBWire
AKBA FINAL DEADLINE: ROSEN, RESPECTED INVESTOR COUNSEL, Encourages Akebia Therapeutics, Inc. Investors to Secure Counsel Before Important Friday Deadline in Securities Class Action - AKBA
May 09, 2022
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Via
NewMediaWire
Topics
Lawsuit
Bronstein, Gewirtz & Grossman, LLC Reminds Akebia Therapeutics, Inc. (AKBA) Shareholders of Class Action and Encourages May 13, 2022 Deadline
May 09, 2022
From
Bronstein, Gewirtz & Grossman, LLC
Via
Business Wire
ROSEN, A LEADING INVESTOR RIGHTS LAW FIRM, Encourages Akebia Therapeutics, Inc. Investors with Losses to Secure Counsel Before Important May 13 Deadline in Securities Class Action - AKBA
April 30, 2022
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Via
NewMediaWire
Topics
Lawsuit
ROSEN, SKILLED INVESTOR COUNSEL, Encourages Akebia Therapeutics, Inc. Investors with Losses to Secure Counsel Before Important Deadline in Securities Class Action - AKBA
April 26, 2022
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Via
NewMediaWire
Topics
Lawsuit
AKBA INVESTOR NOTICE: ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Akebia Therapeutics, Inc. Investors with Losses to Secure Counsel Before Important Deadline in Securities Class Action - AKBA
April 24, 2022
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Via
NewMediaWire
Topics
Lawsuit
ROSEN, A RESPECTED AND LEADING FIRM, Encourages Akebia Therapeutics, Inc. Investors with Losses to Secure Counsel Before Important Deadline in Securities Class Action - AKBA
April 15, 2022
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Via
NewMediaWire
ROSEN, A RESPECTED AND LEADING FIRM, Encourages Akebia Therapeutics, Inc. Investors with Losses to Secure Counsel Before Important Deadline in Securities Class Action - AKBA
April 09, 2022
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Via
NewMediaWire
ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages Akebia Therapeutics, Inc. Investors with Losses to Secure Counsel Before Important Deadline in Securities Class Action AKBA
April 02, 2022
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Via
NewMediaWire
NASDAQ:AKBA Investor Notice: Lawsuit Alleges Securities Laws Violations by Akebia Therapeutics, Inc.
↗
March 30, 2022
San Diego, CA -- (SBWIRE) -- 03/30/2022 -- An investor, who purchased shares of Akebia Therapeutics, Inc. (NASDAQ:AKBA), filed a lawsuit over alleged violations of Federal Securities Laws by Akebia...
Via
SBWire
Bronstein, Gewirtz & Grossman, LLC Notifies Akebia Therapeutics, Inc. (AKBA) Shareholders of Class Action and Encourages Investors to Contact the Firm
March 22, 2022
From
Bronstein, Gewirtz & Grossman, LLC
Via
Business Wire
ROSEN, A LEADING LAW FIRM, Encourages Akebia Therapeutics, Inc. Investors With Losses to Secure Counsel Before Important Deadline in Securities Class Action – AKBA
March 21, 2022
From
The Rosen Law Firm, P.A.
Via
Business Wire
AKEBIA ALERT: Bragar Eagel & Squire, P.C. Announces that a Class Action Lawsuit Has Been Filed Against Akebia Therapeutics, Inc. and Encourages Investors to Contact the Firm
March 17, 2022
From
Bragar Eagel & Squire, P.C.
Via
Business Wire
AKBA EQUITY ALERT: ROSEN, A TOP RANKED LAW FIRM, Encourages Akebia Therapeutics, Inc. Investors with Losses to Secure Counsel Before Important Deadline in Securities Class Action – AKBA
March 15, 2022
From
Rosen Law Firm
Via
Business Wire
Bronstein, Gewirtz & Grossman, LLC Notifies Shareholders of Akebia Therapeutics, Inc. (AKBA) Investigation
January 27, 2022
From
Bronstein, Gewirtz & Grossman, LLC
Via
Business Wire
Canadian Biotech Disruptor Lexston Life Sciences is unlocking the God Molecule (LEXTF, ICPT, AKBA, QURE, BNTX, SAVA)
January 19, 2022
Via
AB Newswire
Topics
Bonds
Stocks
INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Akebia Therapeutics, Inc. and Encourages Investors who Formerly Held Shares of Keryx Biopharmaceuticals (KERX) to Contact the Firm
July 27, 2021
From
The Schall Law Firm
Via
Business Wire
SHAREHOLDER ALERT: Robbins LLP Announces that Akebia Therapeutics, Inc. (AKBA) is Being Sued for Misleading Keryx Biopharmaceuticals, Inc. (KERX) Shareholders Ahead of Merger
July 26, 2021
From
Robbins LLP
Via
Business Wire
INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Akebia Therapeutics, Inc. and Encourages Investors who Formerly Held Shares of Keryx Biopharmaceuticals (KERX) to Contact the Firm
June 18, 2021
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Via
NewMediaWire
Topics
Lawsuit
Akebia Therapeutics, Inc. (NASDAQ: AKBA) Investor Alert: Investigation over Potential Wrongdoing
↗
May 10, 2021
San Diego, CA -- (SBWIRE) -- 05/10/2021 -- An investigation on behalf of investors in Akebia Therapeutics, Inc. (NASDAQ: AKBA) shares over potential wrongdoing at Akebia Therapeutics, Inc was announced...
Via
SBWire
